Om

Skye Bioscience Inc. is a clinical-stage biotechnology company focused on developing therapies that modulate the endocannabinoid system, with an emphasis on metabolic health and obesity-related conditions. Its current pipeline centers on nimacimab, a peripherally restricted antibody targeting cannabinoid receptor 1, designed to influence pathways involved in fat mobilization, appetite regulation, satiety signaling, and broader metabolic function. The company also develops ophthalmic programs, including SBI-100 Ophthalmic Emulsion, for eye diseases such as glaucoma and ocular hypertension. Skye Bioscience works across areas including obesity, overweight, metabolic disorders, and select ophthalmology applications, positioning its research around GPCR-based drug development and cannabinoid receptor biology. Headquartered in San Diego, California, Skye Bioscience Inc. operates as a focused biopharmaceutical company advancing targeted, mechanism-based candidates for currently addressed therapeutic markets.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SKYE BIOSCIENCE MED ENDAVU: Køb Skye Bioscience ($09R0) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Skye Bioscience, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.